Hansa Biopharma AB (publ)

Stockholm Stock Exchange HNSA.ST

Hansa Biopharma AB (publ) Cash and Short-Term Investments for the year ending December 31, 2023: USD 72.25 M

Hansa Biopharma AB (publ) Cash and Short-Term Investments is USD 72.25 M for the year ending December 31, 2023, a -49.43% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Hansa Biopharma AB (publ) Cash and Short-Term Investments for the year ending December 31, 2022 was USD 142.89 M, a 45.99% change year over year.
Hansa Biopharma AB (publ) Cash and Short-Term Investments for the year ending December 31, 2021 was USD 97.87 M, a -41.38% change year over year.
Hansa Biopharma AB (publ) Cash and Short-Term Investments for the year ending December 31, 2020 was USD 166.95 M, a 161.04% change year over year.
Hansa Biopharma AB (publ) Cash and Short-Term Investments for the year ending December 31, 2019 was USD 63.96 M, a -33.76% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

Stockholm Stock Exchange: HNSA.ST

Hansa Biopharma AB (publ)

CEO	Mr. Søren Tulstrup M.Sc
IPO Date	Oct. 17, 2007
Location	Sweden
Headquarters	PO Box 785
Employees	135
Sector	Healthcare
Industries Biotechnology

Description

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Key trends

Past 5 years